Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg (2009) 8.79

Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36

Diagnosis of osteoporosis and assessment of fracture risk. Lancet (2002) 7.38

Assessment of fracture risk. Osteoporos Int (2004) 5.15

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med (2008) 4.81

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45

Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab (2001) 3.43

Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11

Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med (2012) 2.01

Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary. Arch Osteoporos (2012) 1.69

Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res (2003) 1.56

To stop or not to stop, that is the question. Osteoporos Int (2009) 1.53

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int (2005) 1.52

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50

A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int (1999) 1.38

Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab (2005) 1.34

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int (2003) 1.11

Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int (2003) 1.07

Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. J Bone Miner Metab (2005) 1.05

Unresolved issues in osteoporosis in men. Rev Endocr Metab Disord (2001) 1.05

Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab (2007) 1.02

Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res (2012) 0.97

Bone mass and biochemical parameters of bone metabolism in men with spinal osteoporosis. Eur J Clin Invest (1992) 0.91

Epidemiology of osteoporosis in Japan. J Bone Miner Metab (2005) 0.87

Weekly oral alendronic Acid in male osteoporosis. Clin Drug Investig (2004) 0.86

Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study. J Bone Miner Metab (2009) 0.82

Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. Ther Clin Risk Manag (2010) 0.78

Retracted Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature. Drugs Aging (2012) 0.76

Retraction Note: Three-year Experience with Alendronate Treatment in Postmenopausal Osteoporotic Japanese Women with or without Renal Dysfunction: A Retrospective Study. Drugs Aging (2019) 0.75